Yasuo Takeuchi Director, Vice President and CFO PLAY LIST from the beginning Consolidated Financial Results for the 3rd Quarter of Fiscal 2018 and Full-Year Forecasts Disclaimer Voluntary Adoption of IFRS Highlights Consolidated Financial Results and Business Overview for the 3Q of Fiscal 2018 (FY Ending March 31, 2018) 3Q of Fiscal 2018 (1) Consolidated Financial Results 3Q of Fiscal 2018 (1) Factors Influences Consolidated Operating Profit 3Q of Fiscal 2018 (2) Results by Business Segment 3Q of Fiscal 2018 (2) Medical Business 3Q of Fiscal 2018 (3) Medical Business 3Q of Fiscal 2018 (4) Scientific Solutions Business 3Q of Fiscal 2018 (5) Imaging Business Statement of Financial Position Consolidated Cash Flows Forecast for Fiscal 2018 Forecasts of Consolidated Financial Results for Fiscal 2018 Segment Forecasts for fiscal 2018 @ Appendix 【Supplementary Materials】 R&D Expenditures 【Supplementary Materials】 Forecasts of Consolidated Financial Results for Fiscal 2018 (Full-year basis) Factors Influences Consolidated Operating Profit(YoY) 【Supplementary Materials (JGAAP/IFRS) 】 FY2017 3Q Results (1) Consolidated 【Supplementary Materials (JGAAP/IFRS) 】 FY2017 3Q Results (2) Factors Influencing OP 【Supplementary Materials (JGAAP/IFRS) 】 FY2017 3Q Results (3) Factors Influencing Profit 【Supplementary Materials (JGAAP/IFRS) 】 FY2017 3Q Results (4) By segment 【Supplementary Materials (JGAAP/IFRS) 】 FY2017 Full Year Results (1) Consolidated 【Supplementary Materials (JGAAP/IFRS) 】 FY2017 Full Year Results (2) Factors Influencing Operating Profit 【Supplementary Materials (JGAAP/IFRS) 】 FY2017 Full Year Results (3) Factors Influencing Profit 【Supplementary Materials (JGAAP/IFRS) 】 FY2017 Full Year Results (4) By segment Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 Back Next